The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Displaying 1 - 20 of 2617
The FTC sued today to block Covetrus Inc. and its owners, Clayton, Dubilier & Rice LLC and TPG Inc., from acquiring its closest competitor, MWI Veterinary Supply Inc., for $3.5 billion from MWI’s parent, Cencora Inc.
FTC Bureau of Competition Director Daniel Guarnera issued a following statement in response to the announcement that Platinum Equity and its portfolio company, PlayPower, abandoned the proposed acquisition of BCI Burke.
The FTC has taken steps to preserve competition in the digital advertising ecosystem by requiring Publicis Groupe S.A. to continue providing neutral and nondiscriminatory access to LiveRamp Holdings Inc.’s products and services, and to establish firewalls to prevent Publicis from accessing LiveRamp’s customer data, in order to complete Publicis’s acquisition of the company.
The Federal Trade Commission and a group of seven state enforcers filed a complaint in federal district court against Vyera Pharmaceuticals, LLC, alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim. The Commission vote to issue the complaint was 5-0. The complaint was filed on Jan. 27, 2020, in the U.S. District Court for the Southern District of New York. In a Jan. 14, 2022 ruling, U.S. District Court Judge Denise Cote found Shkreli’s conduct “egregious, deliberate, repetitive, long-running, and ultimately dangerous.” Judge Cote banned Shkreli for life from the pharmaceutical industry.
On January 23, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s ruling.
On October 13, 2026, the FTC and seven states asked a federal judge to hold “Pharma Bro” Martin Shkreli in contempt based on their allegations that he flagrantly and repeatedly violated a 2022 court order that banned him from the pharmaceutical industry.
In 2022, the FTC and twelve state partners filed a lawsuit against pesticide manufacturers Syngenta and Corteva, alleging that each defendant implemented a post-patent loyalty program that paid distributors to forgo buying competing generic products.
Syngenta moved for summary judgment on the claims brought by the FTC and State plaintiffs. On October 22, 2026, the Court issued an opinion and order denying that motion.
Syngenta and Corteva each moved to dismiss the lawsuit. On January 12, 2024, the Court issued an opinion and order denying defendants’ motions to dismiss.
On September 25, 2026, the FTC and state plaintiffs, together with Corteva, filed with the Court an agreed stipulated order settling the Corteva case. The stipulated order requires Corteva to dismantle its existing active-ingredient-based post-patent loyalty programs. For a period of ten years, Corteva is prohibited from conditioning payments or other benefits to a customer on that customer purchasing a high share of its requirements for a given pesticide active ingredient from Corteva or on limiting its purchases of generic equivalents, ending Corteva’s exclusionary conduct that has raised pesticide prices for farmers.
The stipulated order applies to all of Corteva’s post-patent active ingredients, and it applies to existing programs and future programs for the term of the stipulated order (10 years).
If you have concerns about whether Corteva is complying with its obligations under the stipulated order, please contact Paul Frangie at (202) 326-2697 and pfrangie@ftc.gov, Kenneth Libby at 202-326-2694 and klibby@ftc.gov, or bccompliance@ftc.gov.
Displaying 1 - 20 of 2617